132 related articles for article (PubMed ID: 38807273)
1. Efficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy in Korean postmenopausal women.
Park BR; Park HN; Jung JB; Lee ES; Kim JS; Choi GY; Lee JJ; Lee IS
Obstet Gynecol Sci; 2024 May; ():. PubMed ID: 38807273
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy in Korean postmenopausal women.
Park BR; Park HN; Jung JB; Lee ES; Kim JS; Choi GY; Lee JJ; Lee IS
Obstet Gynecol Sci; 2017 Mar; 60(2):213-217. PubMed ID: 28344964
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
Archer DF; Schmelter T; Schaefers M; Gerlinger C; Gude K
Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307
[TBL] [Abstract][Full Text] [Related]
4. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
Oelkers WH
Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis.
Warming L; Ravn P; Nielsen T; Christiansen C
Climacteric; 2004 Mar; 7(1):103-11. PubMed ID: 15259289
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic/pharmacodynamic evaluation of low-dose drospirenone with 17β-estradiol in postmenopausal women with moderate to severe vasomotor symptoms.
Sutter G; Schmelter T; Gude K; Schaefers M; Gerlinger C; Archer DF
Menopause; 2014 Mar; 21(3):236-42. PubMed ID: 23963309
[TBL] [Abstract][Full Text] [Related]
7. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris.
Knuuti J; Kalliokoski R; Janatuinen T; Hannukainen J; Kalliokoski KK; Koskenvuo J; Lundt S
Am J Cardiol; 2007 Jun; 99(12):1648-52. PubMed ID: 17560868
[TBL] [Abstract][Full Text] [Related]
8. Effects of drospirenone/estradiol on steroid receptors and Bcl-2 in the postmenopausal endometrium.
Lima SM; Reis BF; Yamada SS; Postigo S; Grande RM; Botogoski SR; Campaner AB; Hueb CK; Galvão MA
Climacteric; 2011 Oct; 14(5):551-7. PubMed ID: 21469974
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of nasal epithelial cells in naturally postmenopausal women receiving hormone therapy with 1 mg 17beta-estradiol and 2 mg drospirenone: a prospective study.
Caruso S; Serra A; Grillo C; Maiolino L; Agnello C; Di Mari L; Cianci A
Menopause; 2008; 15(5):963-6. PubMed ID: 18391834
[TBL] [Abstract][Full Text] [Related]
10. The effects of 17β-estradiol plus drospirenone on anthropometric and biochemical measures of adiposity in menopausal women.
Karakus M; Gelisgen R; Topcuoglu A; Guralp O; Topcuoglu D; Simsek G; Uludag S; Uzun H
Arch Gynecol Obstet; 2012 Nov; 286(5):1233-9. PubMed ID: 22791413
[TBL] [Abstract][Full Text] [Related]
11. Added benefits of drospirenone for compliance.
Foidart JM
Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
[TBL] [Abstract][Full Text] [Related]
12. Effects of drospirenone/estrogen combinations on bone metabolism.
Christiansen C
Climacteric; 2005 Oct; 8 Suppl 3():35-41. PubMed ID: 16203654
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
Zhou YZ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Lin SQ
Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
[TBL] [Abstract][Full Text] [Related]
14. Drospirenone with 17beta-estradiol in the postmenopausal woman with hypertension.
White WB
Climacteric; 2007 Feb; 10 Suppl 1():25-31. PubMed ID: 17364595
[TBL] [Abstract][Full Text] [Related]
15. Prospective study evaluating olfactometric and rhinomanometric outcomes in postmenopausal women on 1 mg 17beta-estradiol and 2 mg drospirenone HT.
Caruso S; Serra A; Grillo C; De Leo V; Maiolino L; Agnello C; Cianci A
Menopause; 2008; 15(5):967-72. PubMed ID: 18551084
[TBL] [Abstract][Full Text] [Related]
16. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.
Genazzani AR; Schmelter T; Schaefers M; Gerlinger C; Gude K
Climacteric; 2013 Aug; 16(4):490-8. PubMed ID: 23531117
[TBL] [Abstract][Full Text] [Related]
17. Drospirenone, a new progestogen, for postmenopausal women with hypertension.
Mallareddy M; Hanes V; White WB
Drugs Aging; 2007; 24(6):453-66. PubMed ID: 17571911
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
[TBL] [Abstract][Full Text] [Related]
19. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women.
Lin SQ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Zhou YZ; Wang ML; Zhu J; Chen SR; Su H; Yang CS; Wang SH; Zhang YZ; Dong XJ
Climacteric; 2011 Aug; 14(4):472-81. PubMed ID: 21469973
[TBL] [Abstract][Full Text] [Related]
20. Effects of hormone therapy containing 2 mg drospirenone and 1 mg 17β-estradiol on postmenopausal exacerbation of Meniere's disease: Preliminary study.
Grillo CM; Maiolino L; Rapisarda AMC; Caruso G; Palermo G; Caruso S
Exp Ther Med; 2021 Oct; 22(4):1103. PubMed ID: 34504557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
